• Inovio Pharmaceuticals held its annual shareholder meeting on May 20, 2026.
• Shareholders backed the slate of eight director nominees for terms running to the 2027 annual meeting.
• Ernst & Young was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Shareholders endorsed an amended and restated 2023 Omnibus Incentive Plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-232524), on May 20, 2026, and is solely responsible for the information contained therein.